Tenaya Therapeutics Stock Probability of Future Stock Price Finishing Over 1.67

TNYA Stock  USD 1.67  0.26  18.44%   
Tenaya Therapeutics' future price is the expected price of Tenaya Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Tenaya Therapeutics performance during a given time horizon utilizing its historical volatility. Check out Tenaya Therapeutics Backtesting, Tenaya Therapeutics Valuation, Tenaya Therapeutics Correlation, Tenaya Therapeutics Hype Analysis, Tenaya Therapeutics Volatility, Tenaya Therapeutics History as well as Tenaya Therapeutics Performance.
For information on how to trade Tenaya Stock refer to our How to Trade Tenaya Stock guide.
  
At present, Tenaya Therapeutics' Price Book Value Ratio is projected to increase significantly based on the last few years of reporting. The current year's Price Earnings To Growth Ratio is expected to grow to 0.05, whereas Price Earnings Ratio is forecasted to decline to (2.02). Please specify Tenaya Therapeutics' target price for which you would like Tenaya Therapeutics odds to be computed.

Tenaya Therapeutics Target Price Odds to finish over 1.67

The tendency of Tenaya Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 1.67 90 days 1.67 
about 82.97
Based on a normal probability distribution, the odds of Tenaya Therapeutics to move above the current price in 90 days from now is about 82.97 (This Tenaya Therapeutics probability density function shows the probability of Tenaya Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 4.0 . This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Tenaya Therapeutics will likely underperform. Additionally Tenaya Therapeutics has an alpha of 0.1624, implying that it can generate a 0.16 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Tenaya Therapeutics Price Density   
       Price  

Predictive Modules for Tenaya Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Tenaya Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Tenaya Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.081.6712.57
Details
Intrinsic
Valuation
LowRealHigh
0.336.5717.47
Details
Naive
Forecast
LowNextHigh
00.0810.98
Details
9 Analysts
Consensus
LowTargetHigh
19.4121.3323.68
Details

Tenaya Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Tenaya Therapeutics is not an exception. The market had few large corrections towards the Tenaya Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Tenaya Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Tenaya Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.16
β
Beta against Dow Jones4.00
σ
Overall volatility
0.64
Ir
Information ratio 0.02

Tenaya Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Tenaya Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Tenaya Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Tenaya Therapeutics had very high historical volatility over the last 90 days
Tenaya Therapeutics may become a speculative penny stock
Tenaya Therapeutics has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (124.08 M) with profit before overhead, payroll, taxes, and interest of 0.
Tenaya Therapeutics currently holds about 180.92 M in cash with (102.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Tenaya Therapeutics has a frail financial position based on the latest SEC disclosures
Roughly 74.0% of the company shares are owned by institutional investors
Latest headline from finance.yahoo.com: Tenaya Therapeutics Reports Promising Early Data from MyPEAK-1 Phase 1b2 Clinical Trial of TN-201 for Treatment ofMYBPC3-Associated Hypertrophic Cardiomyopathy

Tenaya Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Tenaya Stock often depends not only on the future outlook of the current and potential Tenaya Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Tenaya Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding73.8 M
Cash And Short Term Investments104.6 M

Tenaya Therapeutics Technical Analysis

Tenaya Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Tenaya Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Tenaya Therapeutics. In general, you should focus on analyzing Tenaya Stock price patterns and their correlations with different microeconomic environments and drivers.

Tenaya Therapeutics Predictive Forecast Models

Tenaya Therapeutics' time-series forecasting models is one of many Tenaya Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Tenaya Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Tenaya Therapeutics

Checking the ongoing alerts about Tenaya Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Tenaya Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Tenaya Therapeutics had very high historical volatility over the last 90 days
Tenaya Therapeutics may become a speculative penny stock
Tenaya Therapeutics has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (124.08 M) with profit before overhead, payroll, taxes, and interest of 0.
Tenaya Therapeutics currently holds about 180.92 M in cash with (102.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Tenaya Therapeutics has a frail financial position based on the latest SEC disclosures
Roughly 74.0% of the company shares are owned by institutional investors
Latest headline from finance.yahoo.com: Tenaya Therapeutics Reports Promising Early Data from MyPEAK-1 Phase 1b2 Clinical Trial of TN-201 for Treatment ofMYBPC3-Associated Hypertrophic Cardiomyopathy
When determining whether Tenaya Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tenaya Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tenaya Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tenaya Therapeutics Stock:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tenaya Therapeutics. If investors know Tenaya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tenaya Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.44)
Return On Assets
(0.46)
Return On Equity
(0.84)
The market value of Tenaya Therapeutics is measured differently than its book value, which is the value of Tenaya that is recorded on the company's balance sheet. Investors also form their own opinion of Tenaya Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Tenaya Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tenaya Therapeutics' market value can be influenced by many factors that don't directly affect Tenaya Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tenaya Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tenaya Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tenaya Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.